EUVIMEDEUVIMED entdecken
Crossref

Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer

Reuben Ben-David iD, Ahmed Eraky iD, Brenda Hug iD, Matthew D Galsky, Che-Kai Tsao, Kyrollis Attalla, Peter Wiklund, Reza Mehrazin, John P Sfakianos

BJU International · 2025-12 · 136 (6) · 1098-1106

DOI: 10.1111/bju.16926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 07.10.2025. Verfasst von Reuben Ben-David und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Testicular Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate whether circulating tumour DNA (ctDNA) predicts oncological outcomes in the minimal residual disease (MRD) window after radical orchiectomy or retroperitoneal lymph node dissection (RPLND), and to evaluate the diagnostic performance of ctDNA in reference to imaging studies in clinical stage (CS) I disease.

Methods

Longitudinal tumour‐informed ctDNA assays (Signatera™) were collected prospectively from consecutive patients during 2022–2023. The ctDNA signature was informed from the orchiectomy or RPLND specimen. The MRD window was defined as the initial 90 days after orchiectomy or RPLND. Event‐free survival (EFS) and recurrence‐free survival (RFS) were assessed using the Kaplan–Meier method.

Results

Sixty patients with a median (interquartile range) follow‐up of 18 (13–23) months underwent 287 ctDNA analyses; 45% had seminoma. At initial staging, 65% had CS (clinical stage) I, 20% CS II, 3.3% CS III, and 10% CS IS. Post‐orchiectomy ctDNA clearance was achieved in 80% of patients, and patients with undetectable MRD ctDNA had superior 3‐month (100% vs 25% [95% confidence interval [CI] 7.5–83]) and 12‐month EFS (91% [95% CI 79–100] vs (13% [95% CI 2–78]) compared to detectable ctDNA, respectively. Undetectable MRD window ctDNA in patients with CS I undergoing surveillance was associated with an 18‐month RFS of 88%. The diagnostic performance of ctDNA compared to imaging studies for CS I per patient was: sensitivity 33.3%, specificity 93.5%, positive predictive value 33.3%, and negative predictive value (NPV) 93.5%. Detectable pre‐RPLND ctDNA fully correlated with tumour presence, while undetectable ctDNA corresponded to benign histology or teratoma on pathology. Undetectable RPLND MRD ctDNA was associated with superior 9‐month RFS vs detectable ctDNA (100% vs 25% [95% CI 5–100], respectively). Conclusion ctDNA status in the MRD window predicted survival outcomes after orchiectomy and RPLND. Undetectable MRD window ctDNA demonstrated high NPV relative to imaging studies in CS I disease. Further investigation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsCirculating Tumor DNAHumansMaleAdultNeoplasm, ResidualMiddle AgedOrchiectomyProspective StudiesLymph Node ExcisionYoung AdultNeoplasm Staging

Stichwörter der Autor:innen

circulating tumour DNActDNAretroperitoneal lymph node dissectiontesticular neoplasmstumour biomarkers

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Reuben Ben-David, Ahmed Eraky, Brenda Hug

Zitieren

APA

Ben-David, R., Eraky, A., Hug, B., Galsky, M. D., Tsao, C. K., Attalla, K., Wiklund, P., Mehrazin, R., & Sfakianos, J. P. (2025). Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer. BJU International, 136(6), 1098-1106. https://doi.org/10.1111/bju.16926

Vancouver

Ben-David R, Eraky A, Hug B, Galsky MD, Tsao CK, Attalla K, et al. Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer. BJU International. 2025;136(6):1098-1106. doi:10.1111/bju.16926

BibTeX
@article{BenDavid2025,
  author = {Ben-David, Reuben and Eraky, Ahmed and Hug, Brenda and Galsky, Matthew D and Tsao, Che-Kai and Attalla, Kyrollis and Wiklund, Peter and Mehrazin, Reza and Sfakianos, John P},
  title = {Clinical utility of tumour‐informed circulating tumour DNA in patients with testicular cancer},
  journal = {BJU International},
  year = {2025},
  volume = {136},
  number = {6},
  pages = {1098--1106},
  doi = {10.1111/bju.16926}
}
Kostenlos starten →